Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Ruxolitinib and decitabine in patients with post-MPN AML

Prithviraj Bose • 18 Aug 2020
Acute Myeloid Leukemia Leukemia Myeloproliferative Neoplasms

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the rationale, study design and results from a Phase I/II study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Prithviraj Bose

2:55
Current and emerging treatments for MF: an update from ASH 2023
Prithviraj Bose • 11 Dec 2023
2:21
An update from LIMBER-104: zilurgisertib +/- ruxolitinib in the management of MF-associated anemia
Prithviraj Bose • 11 Dec 2023
3:49
Bezuclastinib in adult patients with non-advanced systemic mastocytosis: initial results from Summit
Prithviraj Bose • 11 Dec 2023
3:30
LIMBER-104: zilurgisertib +/- ruxolitinib in patients with MF-associated anemia
Prithviraj Bose • 6 Sep 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals